Document and Entity Information
Document and Entity Information - shares | 6 Months Ended | |
Jun. 30, 2019 | Aug. 08, 2019 | |
Document And Entity Information | ||
Entity Registrant Name | Immune Therapeutics, Inc. | |
Entity Central Index Key | 0001559356 | |
Document Type | 10-Q | |
Document Period End Date | Jun. 30, 2019 | |
Amendment Flag | false | |
Current Fiscal Year End Date | --12-31 | |
Entity Current Reporting Status | Yes | |
Entity Interactive Data Current | Yes | |
Entity Filer Category | Non-accelerated Filer | |
Entity Small Business Flag | true | |
Entity Emerging Growth Company | false | |
Entity Ex Transition Period | false | |
Entity Shell Company | false | |
Entity Common Stock, Shares Outstanding | 445,577,799 | |
Document Fiscal Period Focus | Q2 | |
Document Fiscal Year Focus | 2019 |
Condensed Consolidated Balance
Condensed Consolidated Balance Sheets (Unaudited) - USD ($) | Jun. 30, 2019 | Dec. 31, 2018 |
Current Assets: | ||
Cash and cash equivalents | $ 21,397 | $ 5,859 |
Inventories | 82,801 | |
Total current assets | 21,397 | 88,660 |
Fixed Assets: | ||
Computer equipment, net of accumulated depreciation of $11,138 and $10,477 respectively | 2,075 | 2,766 |
Investment in affiliate, equity method | ||
Deposits | 200 | 200 |
Total assets | 23,672 | 91,626 |
Current Liabilities: | ||
Accounts payable | 2,147,968 | 2,065,476 |
Accrued liabilities | 3,915,020 | 3,302,355 |
Notes payable, net of debt discount | 5,581,133 | 5,187,727 |
Derivative liability | 908,873 | 786,706 |
Total current liabilities | 12,552,994 | 11,342,264 |
Total liabilities | 12,552,994 | 11,342,264 |
Stockholders' Deficit: | ||
Common stock - par value $0.0001; 500,000,000 shares authorized; 455,577,799 and 434,322,574 shares issued and outstanding respectively | 45,558 | 43,433 |
Additional paid in capital | 370,134,346 | 369,881,037 |
Stock issuance due | 35,303 | 35,303 |
Accumulated deficit | (382,744,529) | (381,210,411) |
Total stockholders' deficit | (12,529,322) | (11,250,638) |
Total liabilities and stockholders' deficit | $ 23,672 | $ 91,626 |
Condensed Consolidated Balanc_2
Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - USD ($) | Jun. 30, 2019 | Dec. 31, 2018 |
Statement of Financial Position [Abstract] | ||
Accumulated depreciation | $ 11,138 | $ 10,477 |
Common stock, par value | $ 0.0001 | $ 0.0001 |
Common stock, shares authorized | 500,000,000 | 500,000,000 |
Common stock, shares issued | 445,577,799 | 434,322,574 |
Common stock, shares outstanding | 445,577,799 | 434,322,574 |
Condensed Consolidated Statemen
Condensed Consolidated Statements of Operations (Unaudited) - USD ($) | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2019 | Jun. 30, 2018 | Jun. 30, 2019 | Jun. 30, 2018 | |
Income Statement [Abstract] | ||||
Revenues, net | $ 65,013 | |||
Cost of products sold | 33,172 | |||
Gross profit | 31,841 | |||
Operating expenses | ||||
Selling, general and administrative | 496,996 | 1,120,136 | 983,581 | 1,758,364 |
Research and development expense | 56,501 | 185,692 | ||
Stock issued for services G&A | 401,332 | 120,000 | 653,575 | |
Depreciation and amortization expense | 304 | 433 | 691 | 867 |
Total operating expense | 497,300 | 1,578,402 | 1,104,272 | 2,598,498 |
Loss from operations | (497,300) | (1,578,402) | (1,104,272) | (2,566,657) |
Other income (expense): | ||||
Interest expense | (157,145) | (241,511) | (272,354) | (461,972) |
Loss on deconsolidation | (2,791,172) | (2,791,172) | ||
Gain/(Loss) on valuation derivative | (170,264) | 263,474 | (157,492) | 758,288 |
Loss on settlement of debt | (18,036) | |||
Total other expense | (327,409) | (2,769,209) | (429,846) | (2,512,892) |
Net loss | (824,709) | (4,347,611) | (1,534,118) | (5,079,549) |
Net loss attributable to non-controlling interest | (329,097) | (450,382) | ||
Net loss attributable to common stockholders | $ (824,709) | $ (4,018,514) | $ (1,534,118) | $ (4,629,167) |
Basic and diluted loss per share attributable to common stockholders | $ 0 | $ (0.01) | $ 0 | $ (0.01) |
Weighted average number of shares outstanding | 455,577,799 | 395,149,691 | 451,623,894 | 391,385,764 |
Consolidated Statements of Stoc
Consolidated Statements of Stockholders' Equity/ (Deficit) - USD ($) | Common Stock [Member] | Additional Paid-in Capital [Member] | Stock To Be Issued [Member] | Prepaid Services [Member] | Accumulated Deficit [Member] | Non-Controlling Interest [Member] | Total |
Balance at Dec. 31, 2017 | $ 38,679 | $ 366,625,144 | $ 103,226 | $ (226,667) | $ (373,035,183) | $ (4,608,585) | $ (11,103,386) |
Balance, shares at Dec. 31, 2017 | 386,782,473 | ||||||
Issuance of common stock for prepaid services | $ 323 | $ 324,053 | $ 102,533 | $ 426,909 | |||
Issuance of common stock for prepaid services, shares | 3,238,640 | ||||||
Amortization of prepaid services | $ 226,667 | $ 226,667 | |||||
Issuance of common stock for interest expense | $ 20 | 5,980 | 6,000 | ||||
Issuance of common stock for interest expense, shares | 200,000 | ||||||
Issuance of common stock in exchange for debt | $ 861 | $ 450,553 | 451,414 | ||||
Issuance of common stock in exchange for debt, shares | 8,607,200 | ||||||
Issuance of Cytocom common stock for cash and exercise of warrants | $ 240,500 | 240,500 | |||||
Issuance and modification of common stock warrants | 165,000 | 165,000 | |||||
Elimination of Cytocom noncontrolling interest and deconsolidation | 5,058,967 | 5,058,967 | |||||
Net loss | (4,629,167) | (450,382) | (5,079,549) | ||||
Balance at Jun. 30, 2018 | $ 39,883 | $ 367,811,230 | $ 205,759 | $ (377,664,350) | (9,607,478) | ||
Balance, shares at Jun. 30, 2018 | 398,828,313 | ||||||
Balance at Dec. 31, 2018 | $ 43,433 | $ 369,881,037 | $ 35,303 | $ (381,210,441) | (11,250,638) | ||
Balance, shares at Dec. 31, 2018 | 434,322,574 | ||||||
Issuance of common stock for prepaid services | $ 300 | $ 119,700 | 120,000 | ||||
Issuance of common stock for prepaid services, shares | 3,000,000 | ||||||
Issuance of common stock in exchange for debt | $ 1,825 | $ 60,609 | 62,434 | ||||
Issuance of common stock in exchange for debt, shares | 18,255,225 | ||||||
Issuance of warrants in connection with debt agreement | $ 73,000 | 73,000 | |||||
Net loss | (1,534,118) | (1,534,118) | |||||
Balance at Jun. 30, 2019 | $ 45,558 | $ 370,134,346 | $ 35,303 | $ (382,744,529) | $ (12,529,322) | ||
Balance, shares at Jun. 30, 2019 | 455,577,799 |
Condensed Consolidated Statem_2
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) | 6 Months Ended | |
Jun. 30, 2019 | Jun. 30, 2018 | |
CASH FLOWS FROM OPERATING ACTIVITIES | ||
Net loss | $ (1,534,118) | $ (5,079,549) |
Adjustments to reconcile net loss to net cash flows used in (provided by) operating activities: | ||
Depreciation | 691 | 867 |
Stock issued, and amortization of stock issued, for prepaid services | 226,667 | |
Stock issued for services | 120,000 | 426,909 |
Amortization of debt discount | 163,019 | 222,777 |
Change in value of derivative | 157,492 | (758,288) |
Loss on deconsolidation | 2,791,172 | |
Loss on settlement of debt | 18,036 | |
Stock issued for origination fees and interest expense | 6,000 | |
Expenses paid by lender | 54,661 | |
Changes in operating assets and liabilities: | ||
Accounts payable | 386,972 | 521,798 |
Inventories | 82,801 | 19,450 |
Unpaid interest accrued on debt | 26,019 | |
Accrued liabilities | 612,662 | 679,413 |
Net cash from (used in) operating activities | 15,538 | (870,087) |
CASH FLOWS FROM INVESTING ACTIVITES | ||
Deconsolidation of subsidiary | (11,631) | |
Purchase of computer equipment | (1,970) | |
Net cash used in investing activities | (13,601) | |
CASH FLOWS FROM FINANCING ACTIVITES | ||
Proceeds from sale of stock and exercise of warrants | 240,500 | |
Proceeds from issuance of notes payable | 628,470 | |
Net cash provided by financing activities | 868,970 | |
Net increase (decrease) in cash | 15,538 | (14,718) |
Cash and cash equivalents at beginning of period | 5,859 | 14,718 |
Cash and cash equivalents at end of period | 21,397 | 0 |
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION: | ||
Cash paid for interest | 16,000 | 34,711 |
SUPPLEMENTAL DISCLOSURE OF NON-CASH INVESTING AND FINANCING ACTIVITES: | ||
Debt discount | 73,000 | 165,000 |
Conversion of debt and accrued interest to common stock | 27,110 | 214,215 |
Settlement of derivative liability | 243,199 | |
Deconsolidation of Cytocom, Inc. | 2,278,237 | |
Reclassification from notes payable to accounts payable | 254,749 | 17,284 |
Loss on debt conversion | 18,036 | |
Accounts payable paid directly by lender | 54,661 | |
Debt settled and reclassed to accrued expenses | $ 35,325 |
Organization and Description of
Organization and Description of Business | 6 Months Ended |
Jun. 30, 2019 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
Organization and Description of Business | 1. Organization and Description of Business Immune Therapeutics, Inc. (the “Company,” “we,” or “our”) was initially incorporated in Florida on December 2, 1993 as Resort Clubs International, Inc. (“Resort Clubs”). It was formed to manage and market golf course properties in resort markets throughout the United States. Galliano International Ltd. (“Galliano”) was incorporated in Delaware on May 27, 1998 and began trading in November 1999 through the filing of a 15C-211. On November 10, 2004, Galliano merged with Resort Clubs. Resort Clubs was the surviving corporation. On August 23, 2010, Resort Clubs changed its name to pH Environmental Inc. (“pH Environmental”). On April 23, 2012, pH Environmental completed a name change to TNI BioTech, Inc., and on April 24, 2012, we executed a share exchange agreement for the acquisition of all of the outstanding shares of TNI BioTech IP, Inc. On September 4, 2014, a majority of our shareholders approved an amendment to our Amended and Restated Articles of Incorporation, as amended, to change our name to Immune Therapeutics, Inc. We filed our name change amendment with the Secretary of State of Florida on October 27, 2014 changing our name to Immune Therapeutics, Inc. The Company currently operates out of Orlando, Florida. In July 2012, the Company’s focus turned to acquiring patents that would protect and advance the development of new uses of opioid-related immune- therapies, such as low dose naltrexone (“LDN”) and Methionine [Met5]-enkephalin (“MENK”). The Company’s therapies are believed to stimulate and/or regulate the immune system in such a way that they provide the potential to treat a variety of diseases. We believe our therapies may be able to correct abnormalities or deficiencies in the immune system in diseases such as HIV infection, autoimmune disease, immune disorders, or cancer; all of which can lead to disease progression and life-threatening situations when the immune system is not functioning optimally. In October 2012, the Company formed TNI BioTech International, Ltd., a BVI company in Tortola, British Virgin Islands, which was set up to allow the Company to market and sell LDN in those countries outside the U.S. in which we have been able to obtain approval to sell the Company’s products. In August 2013, the Company formed its United Kingdom subsidiary, TNI BioTech, LTD (the “UK Subsidiary”). The UK Subsidiary received approval to be considered a micro, small or medium-sized enterprise (“SME”) with the European Medicines Agency (“EMA”) on August 21, 2013. The designation provides the UK Subsidiary with significant discounts when holding meetings or submitting filings to the EMA. On September 19, 2013, the UK Subsidiary submitted a pre-submission package to the EMA regarding Crohn’s Disease. The EMA granted the UK Subsidiary a meeting that took place on September 27, 2013. The UK Subsidiary is eligible to benefit from the provisions for administrative and financial assistance for SMEs set out in Regulation (EC) No 2049/2005. The Company will apply to obtain EMA benefits once funding becomes available. In December 2013, the Company formed a subsidiary, Cytocom Inc. (“Cytocom”), to focus on conducting LDN and MENK clinical trials in the United States. In December 2014, the Company finalized the distribution of common stock of Cytocom to its shareholders. As part of the transaction (“Original Agreement”), the Company transferred to Cytocom certain of its rights, title and interest in or relating to intellectual property (i) patents, patent applications, and all divisional, continuations and continuations-in-part thereof, together with all reissues, reexaminations, renewals and extensions thereof and all rights to obtain such divisionals, continuations and continuations-in-part, reissues, reexaminations, renewals and extensions, and all utility models and statutory invention registrations and any other such analogous rights, (ii) trademarks, service marks, Internet domain names, trade dress, trade styles, logos, trade names, services names, brand names, corporate names, assumed business names and general intangibles and other source identifiers of a like nature, together with the goodwill associated with any of the foregoing, and all registrations and applications for registrations thereof, together with all renewals and extensions thereof and all rights to obtain such renewals and extensions, (iii) copyrights, mask work rights, database and design rights, moral rights and rights in Internet websites, whether registered or unregistered and whether published or unpublished, all registrations and recordings thereof and all applications in connection therewith, together with all renewals, continuations, reversions and extensions thereof and all rights to obtain such renewals, continuations, reversions and extensions, and (iv) confidential and proprietary information, including, trade secrets and know-how. The Original Agreement also granted the Company rights to market Lodonal™ and Met-Enkephalin (“MENK”) in “Emerging Markets,” which included all countries excluding Canada, Italy, Japan, France, Germany, United Kingdom, European Community and the United States. Pursuant to the Original Agreement, the Company was required to pay Cytocom a 5% royalty on all sales all ongoing drug development and fees due in connection with the underlying patents until such time as Cytocom was funded. On December 8, 2014, the number of Cytocom shares of common stock that were issued to our shareholders totaled 113,242,522 shares. In connection with the Original Agreement, Cytocom issued an additional 140,100,000 shares of its common stock to the Company, which gave the Company a 55.3% stake in Cytocom on that date. In April 2016, the Board of Directors and a majority of shareholders of Cytocom approved a reverse stock split of Cytocom’s outstanding common stock with one new share of stock for each twenty old shares of common stock. Cytocom effectuated and finalized the reverse split in June 2016. On May 1, 2018, the Company entered into an amended and restated licensing agreement (the “Restated Agreement”) with Cytocom. The Restated Agreement restates the licensing arrangement between the Company and Cytocom as provided by the Original Agreement. The Restated Agreement grants the Company distribution and marketing rights for Lodonal™ and MENK for humans in Emerging Markets. In addition, the Company has been granted the rights to distribute and market Lodonal™ and MENK for animal use in the United States. The royalty due to Cytocom has been reduced from 5% to 1% of sales and the Company no longer has any ongoing obligations to pay for costs in connection with the assets of Cytocom. On June 4, 2018, the Company and Cytocom entered into a Stock Purchase Agreement (the “Stock Agreement. Pursuant to the Stock Agreement, the Company cancelled approximately $4,000,000 of debt owed to it by Cytocom in exchange for ten percent (10%) of the issued and outstanding common stock of Cytocom, as calculated on a fully diluted basis. The Restated Agreement was a condition of the Stock Agreement. At June 30, 2019, the Company’s equity interest in Cytocom stood at 15.26% of Cytocom’s common stock issued and outstanding on that date. The Company’s policies with respect to accounting for its equity interest in Cytocom is described in Note 2 to the “Notes to the Condensed Consolidated Financial Statements” below (“Summary of Significant Accounting Policies: Non-Controlling Interest in Consolidated Subsidiaries”). On April 8, 2019, the Company signed a second amendment to its licensing agreement (the “Second Amendment” with Cytocom. The Second Amendment confirmed that, as of its effective date (December 31, 2018) the Company owned 15.57% of the common shares issued and outstanding on that date. The Company agreed to assume the obligation to repay all accounts payable obligations and accrued liabilities owed by Cytocom as of the effective date, except those accounts’ payable obligations and accrued liabilities as specified in the Second Amendment. The Company also assumed the obligation to repay all notes payable, together with any interest or fees payable thereon, owed by Cytocom as of the effective date, except those notes’ payable obligations, together with any interest or fees payable thereon, as specified by the Second Amendment. The parties further agreed that in the event of a change of control of Cytocom, and at the option of Cytocom, the Company would have the right to purchase outright the Company’s licensing rights to Emerging Markets for humans under the License Agreement at a price equal to value of those licensing rights as determined by and independent valuator acceptable to the Company and Cytocom. In March 2014, the Company incorporated Airmed Biopharma Limited, an Irish corporation with an address in Dublin, Ireland, and Airmed Holdings Limited, an Irish company domiciled in Bermuda. The Irish companies were set up to benefit from incentives granted by the Irish government for the establishment of pharmaceutical companies (many of the world’s leading pharmaceutical companies have located in Ireland), and so that the Company could take advantage of Ireland’s status as a member of the European Union and the European Economic Area. An Irish limited liability company enjoys a low corporate income tax rate of 12.5%, one of the lowest in the world. The Irish-domiciled company hopes to qualify for tax incentives for Irish holding/headquartered companies and to benefit from the network of double tax treaties that reduce withholding taxes. TNI BioTech International, Ltd. will manage our international distribution, using product that is manufactured in Ireland and elsewhere. At present, the Company is a late development-stage biopharmaceutical company focused on the licensing, development and commercialization of innovative prescription medications for humans in Africa, Central and South America, the Caribbean and China (hereinafter referred to as “Emerging Markets”) and worldwide for animals and companion pet therapeutics. The Company is not permitted to market its licensed products in the United States. Going Concern The Company has incurred significant net losses since inception and has relied on its ability to fund its operations through private equity financings. Management expects operating losses and negative cash flows to continue at more significant levels in the future. As the Company continues to incur losses, transition to profitability is dependent upon the successful development, approval, and commercialization of its product candidate and the achievement of a level of revenues adequate to support the Company’s cost structure. The Company may never achieve profitability, and unless and until it does, the Company will continue to need to raise additional cash. Management intends to fund future operations through additional private or public debt or equity offerings and may seek additional capital through arrangements with strategic partners or from other sources. Based on the Company’s operating plan, existing working capital at June 30, 2019 was not sufficient to meet the cash requirements to fund planned operations through for the next 12 months without additional sources of cash. These conditions raise substantial doubt about the Company’s ability to continue as a going concern. The accompanying financial statements have been prepared assuming that the Company will continue as a going concern and do not include adjustments that might result from the outcome of this uncertainty. This basis of accounting contemplates the recovery of the Company’s assets and the satisfaction of liabilities in the normal course of business. The Company experienced a net loss attributable to common shareholders of $1,534,118 and added cash and cash equivalents for operations in the amount of $15,538 during the 6 months ended June 30, 2019, resulting in stockholders’ deficit of $12,529,322 at that date. |
Summary of Significant Accounti
Summary of Significant Accounting Policies | 6 Months Ended |
Jun. 30, 2019 | |
Accounting Policies [Abstract] | |
Summary of Significant Accounting Policies | 2. Summary of Significant Accounting Policies Basis of Presentation The consolidated financial statements included herein have been prepared by the Company, without audit, pursuant to the rules and regulations of the Securities and Exchange Commission. Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. generally accepted accounting principles have been omitted. However, in the opinion of management, all adjustments (which include only normal recurring adjustments, unless otherwise indicated) necessary to present fairly the financial position and results of operations for the periods presented have been made. The results for interim periods are not necessarily indicative of trends or of results to be expected for the full year. These financial statements should be read in conjunction with the financial statements of the Company for the year ended December 31, 2018 (including the notes thereto) set forth in Form 10- K. We have identified the policies below as critical to our business operations and the understanding of its results of operations. The Company’s senior management has reviewed these critical accounting policies and related disclosures with the Company’s Board of Directors. The impact and any associated risks related to these policies on our business operations are discussed throughout this section where such policies affect our reported and expected financial results. The Company qualifies as an “emerging growth company” as defined in Section 101 of the Jumpstart our Business Startups Act (“JOBS Act”) as we do not have more than $1,000,000,000 in annual gross revenue for the year ended December 31, 2018. We are electing to use the extended transition period for complying with new or revised accounting standards under Section 102(b)(1) of the JOBS Act. Non-Controlling Interest in Consolidated Subsidiaries Prior to May 1, 2018, the Company consolidated Cytocom. On May 1, 2018, the Company entered into an amended and restated licensing agreement (the “Restated Agreement”) with Cytocom, Inc., in accordance with which the Company no longer has any ongoing obligations to pay for costs in connection with the assets of Cytocom. On June 4, 2018, the Company and Cytocom entered into a Stock Purchase Agreement (the “Stock Agreement”). Pursuant to the Stock Agreement, the Company cancelled approximately $4,000,000 of debt owed to it by Cytocom in exchange for ten percent (10%) of the issued and outstanding common stock of Cytocom, as calculated on a fully diluted basis on June 4, 2018. At June 30, 2019, the Company’s equity interest in Cytocom stood at 15.26% of Cytocom’s common stock issued and outstanding. Accordingly, the Company deconsolidated Cytocom as of May 1, 2018, and accounts for its retained interest in Cytocom under the equity method of accounting, with the Company’s share of Cytocom’s earnings recorded in “loss from equity method investment” in the consolidated statements of operations. As the balance of the Company’s investment in Cytocom has been $0 since December 31, 2018, no losses have been recognized during the quarter ended June 30, 2019. Revenue Recognition We recognize revenue on sales to customers and distributors upon satisfaction of our performance obligations when the goods are shipped. For consignment sales, we recognize revenue when the goods are pulled from consignment inventory. Sales of LodonalTM pills or capsules product are included in revenue when production is sold to a customer in fulfillment of performance obligations under the terms of agreed contracts. Performance obligations primarily comprise delivery of product at a delivery point, as negotiated within each contract. Each quantity of product sold is separately identifiable and represents a distinct performance obligation to which the transaction price is allocated. Performance obligations are satisfied at a point in time once control of the product has been transferred to the customer. The Company considers a variety of facts and circumstances in assessing the point of control transfer, including but not limited to: whether the purchaser can direct the use of the product, the transfer of significant risks and rewards, the Company’s right to payment, and transfer of legal title. In each case, the time between delivery and when payments are due is not significant. Leases In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842). This standard requires all leases that have a term of over 12 months to be recognized on the balance sheet with the liability for lease payments and ‘the corresponding right-of-use asset initially measured at the present value of amounts expected to be paid over the term. Recognition of the costs of these leases on the income statement will be dependent upon their classification as either an operating or a financing lease. Costs of an operating lease will continue to be recognized as a single operating expense on a straight-line basis over the lease term. Costs for a financing lease will be disaggregated and recognized as both an operating expense (for the amortization of the right-of-use asset) and interest expense (for interest on the lease liability). On January 1, 2019, the Company applied ASU 842 on a modified retrospective basis to leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements. At June 30, 2019, we had no leases that fall within the scope of this standard. Accordingly, the standard has no impact on our consolidated financial position or our results of operations. Use of Estimates The preparation of the Company’s financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from such estimates. Cash, Cash Equivalents, and Short-Term Investments The Company considers all highly liquid investments with original maturities at the date of purchase of three months or less to be cash equivalents. Cash and cash equivalents include bank demand deposits, marketable securities with maturities of three months or less at purchase, and money market funds that invest primarily in certificates of deposits, commercial paper and U.S. government and U.S. government agency obligations. Cash equivalents are reported at fair value . Concentration of Credit Risk Financial instruments that potentially subject the Company to concentrations of credit risk are primarily cash and cash equivalents. The Company is exposed to credit risk, subject to federal deposit insurance, in the event of a default by the financial institutions holding its cash and cash equivalents to the extent of amounts recorded on the condensed consolidated balance sheets. The cash accounts are insured by the Federal Deposit Insurance Corporation up to $250,000. At June 30, 2019, the Company has no cash balances in excess of insured limits. Segment and Geographic Information Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company views its operations and manages its business in one operating segment and does not segment the business for internal reporting or decision making. Fair Value of Financial Instruments In accordance with the reporting requirements of Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) Topic 825, “Financial Instruments”, the Company calculates the fair value of its assets and liabilities which qualify as financial instruments under this standard and includes this additional information in the notes to the financial statements when the fair value is different than the carrying value of those financial instruments. Cash, cash equivalents and accounts payable are accounted for at cost which approximates fair value due to the relatively short maturity of these instruments. The carrying value of notes payable also approximate fair value since they bear market rates of interest and other terms. None of these instruments are held for trading purposes. Derivative Financial Instruments FASB ASC 820, Fair Value Measurements Inventory Inventories comprise finished product, raw materials and materials used for packaging. Inventories are stated at the lower of cost or market with cost based on the first-in, first-out (FIFO) method. Inventory that can be used in either the production of clinical or commercial products is expensed as research and development costs when identified for use in a clinical trials or clinical manufacturing campaigns. Inventory used in marketing activities is charged to selling, general and administrative expense. Inventory as of June 30, 2019 was valued at $0, a decrease of $158,648 or 100% from the inventory balance at the end of June 2018, as the inventory was deemed obsolete and written off as a result. Fixed Assets Fixed assets are stated at cost, less accumulated depreciation. Depreciation is determined on a straight-line basis over the estimated useful lives of the assets, which generally range from three to five years. Maintenance and repairs are charged against expense as incurred. Depreciation expense for the quarters ended June 30, 2019 and June 30, 2018 was $691 and $433, respectively. Impairment of Long-Lived Assets The Company evaluates long-lived assets for impairment whenever events or change in circumstances indicate that the carrying amount of an asset may not be recoverable as prescribed by ASC Topic 360-10-05, “Property, Plant and Equipment.” If the carrying amount of the asset, including any intangible assets associated with that asset, exceeds its estimated undiscounted net cash flow, before interest, the Company will recognize an impairment loss equal to the difference between its carrying amount and its estimated fair value. Research and Development Costs Research and development costs are charged to expense as incurred and are typically comprised of salaries and benefits, pre-clinical studies, clinical trial activities, drug development and manufacturing, fees paid to consultants and other entities that conduct certain research and development activities on the Company’s behalf and third-party service fees, including clinical research organizations and investigative sites. Costs for certain development activities, such as clinical trials are recognized based on an evaluation of the progress to completion of specific tasks using data such as patient enrollment, clinical site activations, or information provided by vendors on their actual costs incurred. Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected in the financial statements as operating expenses. Income Taxes The Company follows ASC Topic 740, Income Taxes, which requires recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred tax assets and liabilities are based on the differences between the financial statements and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Deferred tax assets are reduced by a valuation allowance to the extent management concludes it is more likely than not that the asset will not be realized. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The standard addresses the determination of whether tax benefits claimed or expected to be claimed on a tax return should be recorded in the financial statements. Under ASC Topic 740, the Company may recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the tax authorities, based on the technical merits of the position. The tax benefits recognized in the financial statements from such a position should be measured based on the largest benefit that has a greater than fifty percent likelihood of being realized upon ultimate settlement. ASC Topic 740 also provides guidance on de-recognition, classification, interest and penalties on income taxes, accounting in interim periods and requires increased disclosures. At the date of adoption, and as of June 30, 2019 and 2018, the Company does not have a liability for unrecognized tax uncertainties. The Company’s policy is to record interest and penalties on uncertain tax positions as income tax expense. As of June 30, 2019, and 2018, the Company has not accrued any interest or penalties related to uncertain tax positions. Stock-Based Compensation and Issuance of Stock for Non-Cash Consideration The Company measures and recognizes compensation expense for all share-based payment awards made to employees and directors, including employee stock options, based on estimated fair values equaling either the market value of the shares issued or the value of consideration received, whichever is more readily determinable. The majority of the non-cash consideration pertains to services rendered by consultants and others and has been valued at the fair value of the Company’s common stock at the date of the agreement. The Company’s accounting policy for equity instruments issued to consultants and vendors in exchange for goods and services follows the provisions of ASC Topic 505-50, “Equity-Based Payments to Non-Employees.” The measurement date for the fair value of the equity instruments issued is determined at the earlier of (i) the date at which a commitment for performance by the consultant or vendor is reached or (ii) the date at which the consultant or vendor’s performance is complete. Net Loss per Share of Common Stock Basic net loss per share is calculated by dividing the net loss attributable to common stockholders by the weighted average number of common shares outstanding for the period, without consideration for common stock equivalents. Diluted net loss per share is calculated by dividing the net loss by the weighted-average number of common share equivalents outstanding for the period determined using the treasury-stock method and the if-converted method. Dilutive common stock equivalents are comprised of common stock purchase warrants and options outstanding. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding due to the Company’s net loss position The Company’s potential dilutive securities which include warrants (as described in Note 8 to the Financial Statements – “Capital Structure – Common Stock and Common Stock Purchase Warrants”) and convertible debt (as described in Note 6 to the Financial Statements – “Notes Payable”), have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss per share. Recent Accounting Standards During the quarter ended June 30, 2019, there were several new accounting pronouncements issued by the Financial Accounting Standards Board. Each of these pronouncements, as applicable, has been or will be adopted by the Company. Management does not believe the adoption of any of these accounting pronouncements has had or will have a material impact on the Company’s consolidated financial statements. |
Fixed Assets
Fixed Assets | 6 Months Ended |
Jun. 30, 2019 | |
Fixed Assets: | |
Fixed Assets | 3. Fixed Assets June 30, 2019 December 31, 2018 Fixed Assets: Computer equipment $ 13,213 $ 13,213 Less accumulated depreciation (11,138 ) (10,447 ) Fixed assets, net $ 2,075 $ 2,766 The Company utilizes the straight-line method for depreciation, using three to five-year depreciable asset lives. Depreciation expense was not material for all periods presented. |
Investments_ Deconsolidation of
Investments: Deconsolidation of Cytocom | 6 Months Ended |
Jun. 30, 2019 | |
Investments Deconsolidation Of Cytocom | |
Investments: Deconsolidation of Cytocom | 4. Investments: Deconsolidation of Cytocom In accordance with the May 1, 2018 “Restated Agreement” with Cytocom, the Company no longer has any ongoing obligations to pay for costs in connection with the assets of Cytocom. Accordingly, effective May 1, 2018, the Company deconsolidated Cytocom. However, the Company exercises influence through its retained equity interest and through representation on Cytocom’s board of directors. As a result, the Company uses the equity method to account for its retained interest in Cytocom. On May 1, 2018, the Company recorded an equity method investment in Cytocom of $1,189, the par value of Cytocom common stock multiplied by the number of shares owned by the Company, due to the negative equity associated with Cytocom’s underlying financial position. As a result of the continuing losses in Cytocom, the balance of this investment is currently $0. At June 30, 2019, Cytocom had no significant assets or income. |
Accrued Liabilities
Accrued Liabilities | 6 Months Ended |
Jun. 30, 2019 | |
Payables and Accruals [Abstract] | |
Accrued Liabilities | 5. Accrued Liabilities Accrued expenses and other liabilities consist of the following: June 30, 2019 December 31, 2018 Accrued payroll to officers and others $ 2,819,551 $ 2,010,570 Accrued interest and penalties – notes payable 959,412 877,571 Estimated legal settlements 136,057 136,057 Other accrued liabilities - 15,512 Total accrued expenses and other liabilities $ 3,915,020 $ 3,039,710 |
Notes Payable
Notes Payable | 6 Months Ended |
Jun. 30, 2019 | |
Debt Disclosure [Abstract] | |
Notes Payable | 6. Notes payable Notes payable consist of the following: June 30, 2019 December 31, 2018 Promissory note issued July 29, 2014 to Ira Gaines. In 2016, the maturity date on the note was extended to December 1, 2017. As of June 30, 2019, the note is in default. The note earns interest at a rate of 18% per annum. $ 100,000 $ 100,000 Promissory notes issued between November 26, 2014 and December 31, 2015, to raise up to $2,000,000 in debt. Lenders earn interest at a rate of 10% per annum, plus a pro-rata share of two percent of the Company’s gross receipts for sales of IRT-103-LDN in perpetuity. Notes will be repaid in 36 monthly installments of principal and interest commencing no later than October 15, 2015. These notes were in default at June 30, 2019, as the Company was unable to pay installments on their due dates. 286,000 286,000 Promissory notes issued between May 1, 2015 and December 31, 2016 and maturing between June 14, 2015 and December 1, 2017. Lenders on loans aggregating $375,994 earn interest at rates between 2% and 18% per annum. On loans aggregating $100,000, interest is payable in a fixed amount not tied to a specific interest rate. The Company was unable to repay the notes at maturity and at June 30, 2019 the note was in default. 725,994 725,994 Promissory notes issued to an officer of the Company effective November 3, 2015 and maturing November 3, 2016 for settlement of accrued payroll, bearing interest at 10% per annum and including a stock conversion feature. The Company was unable to repay the note at maturity and at June 30, 2019 the note was in default. 97,737 97,737 Promissory notes issued between July 1, 2016 and December 31, 2016. Lenders earn interest at 2% per annum. The notes mature on December 31, 2017, and at June 30, 2019 the notes were in default. 206,000 206,000 Promissory notes aggregating $1,350,000 issued in the fourth quarter 2016. The notes accrue interest at 2% per annum and mature between November 1, 2017 and December 31, 2017. As June 30, 2019, the notes were in default. 1,354,000 1,354,000 Promissory notes aggregating $500,000 issued in the first quarter of 2017. The notes accrue interest at 2% per annum and mature between January 12, 2018 and June 30, 2018. At June 30, 2019, the notes were in default. 500,000 500,000 Promissory notes issued January 25, 2017. The lenders earn interest at 7% per month. The notes mature on July 5, 2017, and at June 30, 2019 the notes were in default. 50,000 50,000 Promissory notes aggregating $300,000 issued in the second quarter of 2017. The notes accrue interest at 2% per annum and mature between April 3, 2018 and May 31, 2018. At June 30, 2019, the notes were in default. 300,000 300,000 Promissory notes aggregating $191,800 issued in the third quarter of 2017. The notes accrue interest at 2% per annum and mature between June 16, 2018 and December 31, 2018. At June 30, 2019, the notes were in default. 191,800 191,800 Promissory note for $425,000 issued in October 2017 with an original issue discount of $70,000. The note is in default, giving the holder an option to convert the note to stock using the lowest value of the Company’s common stock 25 days prior to the conversion. In 2018, The defaults also resulted in certain penalties, as a result of which the principal amount of the note outstanding at June 30, 2019 had increased to $454,032. $49,943 of accrued interest owed on the note has been converted to stock. The Company has accrued a $908,873 derivative liability for the remaining conversion right. 454,032 455,122 Promissory notes aggregating $105,500 issued in the fourth quarter of 2017. The notes accrue interest at 2% per annum. At June 30, 2019, the notes were in default. 105,500 105,500 Promissory notes aggregating $47,975 issued in the first quarter of 2018. The notes accrue interest at 2% per annum and mature between May 2018 and January 2019. At June 30, 2019, the notes were in default. 47,975 47,975 Promissory notes aggregating $125,000 issued in the first quarter of 2018. The notes accrue interest between 2% and 12% per annum and mature between April 2018 and June 2018. These notes include warrants between 5,000,000 and 20,000,000 shares with an exercise price of $0.0005. At June 30, 2019 the notes were in default 125,000 125,000 Promissory notes aggregating $65,000 issued in the second quarter of 2018. The notes accrue interest between 2% per annum and mature between July 2018 and October 2018. These notes include warrants between 1,000,000 and 5,000,000 shares with an exercise price of $0.005. At June 30, 2019 the notes were in default 65,000 65,000 Promissory notes aggregating $193,000 issued in the third quarter of 2018. The notes accrue interest at 2% per annum and mature between November 2018 and January 2019. These notes include warrants between 600,000 and 5,000,000 shares with an exercise price of $0.005. At June 30, 2019, $103,000 of these notes were in default. 193,000 193,000 Promissory notes aggregating $533,855 issued in the fourth quarter of 2018. The notes accrue interest from 2% to 3.5% per annum and mature between February 2019 and December 2019. These notes include warrants between 200,000 and 39,500,000 shares with an exercise price of $0.005 to $0.04. At June 30, 2019, $479,000 of these notes were in default. 533,855 533,855 Promissory note for $23,000 issued in the first quarter of 2019. The note accrues interest at 2% per annum and matures during July 2019. The note includes warrants for 4,600,000 shares with an exercise price of $0.005. At June 30, 2019, the note was in default. 23,000 - Promissory note for $231,478 issued in the first quarter of 2019. The note accrues interest at 6% per annum and matures in February 2020. 231,478 - Promissory notes aggregating $50,000 issued in the second quarter of 2019. The notes accrue interest at 2% per annum and mature between July and September 2019. These notes include warrants for 10,000,000 shares with an exercise price of $0.005. 50,000 - Less: Original issue discount on notes payable and warrants issued with notes. (59,238 ) (149,256 ) Total $ 5,581,133 $ 5,187,727 As of June 30, 2019, the Company had accrued $959,412 in unpaid interest and default penalties. During the quarter ended June 30, 2019, no shares were issued by the Company in settlement of promissory notes. As of June 30, 2018, the Company had accrued $774,793 in unpaid interest and default penalties. During the quarter ended June 30, 2018, 8,607,200 shares with a fair value of $451,514 were issued by the Company for settlement of promissory notes. |
Derivative Liabilities
Derivative Liabilities | 6 Months Ended |
Jun. 30, 2019 | |
Derivative Instruments and Hedging Activities Disclosure [Abstract] | |
Derivative Liabilities | 7 Derivative Liabilities As of June 30, 2019, and December 31, 2018 the aggregate fair value of the outstanding derivative liability was $908,873 and $786,706, respectively. The Company estimated the fair value of the derivative liability using the Black-Scholes option pricing model using the following key assumption during the quarter June 30, 2019: Three months ended June 30, 2019 Volatility 209.43 % Risk-free interest rate 1.92 % Expected dividends - % Expected term 1 year The Company determines the fair values of its financial instruments based on the fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The following three levels of inputs may be used to measure fair value: Level 1 Quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date. Level 2 Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Level 3 Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. The Company uses Level 3 inputs to estimate the fair value of its derivative liabilities. The following schedule summarizes the valuation of financial instruments at fair value in the balance sheet as of June 30, 2019: Fair Value Measurements as of June 30, 2019 Level 1 Level 2 Level 3 Assets Total assets - - - Liabilities Conversion option derivative liability $ - $ - $ 908,873 Total liabilities $ - $ - $ 908,873 The following table set forth a reconciliation of changes in the fair value of derivative liabilities classified as Level 3 in the fair value hierarchy: Significant Unobservable Input (Level 3) Beginning balance $ 786,706 Change in fair value 157,492 Partial settlements of liability (35,325 ) Ending balance $ 908,873 |
Capital Structure - Common Stoc
Capital Structure - Common Stock and Stock Purchase Warrants | 6 Months Ended |
Jun. 30, 2019 | |
Equity [Abstract] | |
Capital Structure - Common Stock and Stock Purchase Warrants | 8 Capital Structure – Common Stock and Stock Purchase Warrants Each holder of common stock is entitled to vote on all matters and is entitled to one vote for each share held. No holder of shares of stock of any class shall be entitled as a matter of right to subscribe for or purchase or receive any part of any new or additional issue of shares of stock of any class, or of securities convertible into shares of stock or any class, whether now hereafter authorized or whether issued for money, for consideration other than money, or by way of dividend. As of June 30, 2019, and 2018, the Company was authorized to issue 500,000,000 common shares at a par value of $0.0001 per share. As of June 30, 2019, the Company had 455,577,799 shares of common stock outstanding and 434,322,574 outstanding as of December 31, 2018. Stock Warrants In the quarter ended June 30, 2019, 10,000,000 new warrants were issued by the Company. There were no modifications of the terms of any warrants issued by the Company in the quarters ended June 30, 2019 and 2018. Following is a summary of outstanding stock warrants at, and activity during the six months ended, June 30, 2019: Number of Shares Exercise Price Weighted Average Price Warrants as of December 31, 2018 281,782,856 $ 0.001-3.74 $ 0.09 Issued in 2019 14,600,000 $ .005 $ 0.01 Expired and forfeited (4,159,000 ) $ 0.00-2.00 $ 1.25 Exercised - $ - $ - Warrants as of June 30, 2019 292,233,856 $ 0.001-3.74 $ 0.07 Summary of outstanding warrants as of June 30, 2019: Expiration Date Number of Shares Exercise Price Remaining Life (years) Third Quarter 2019 260,000 $ 0.07-0.23 0.25 Fourth Quarter 2019 23,222,726 $ 0.50-1.50 0.50 Second Quarter 2020 300,000 $ 0.50 1.00 Fourth Quarter 2020 1,000,000 $ 0.20 1.50 First Quarter 2021 12,600,000 $ 0.20 1.75 Second Quarter 2021 5,812,252 $ 0.01408-0.20 2.00 Third Quarter 2021 5,166,667 $ 0.03-0.20 2.25 Fourth Quarter 2021 300,000 $ 0.10 2.50 Second Quarter 2022 1,750,000 $ 0.15 3.00 Third Quarter 2022 2,650,000 $ 0.05-0.10 3.25 Fourth Quarter 2022 9,811,422 $ 0.08-0.29 3.50 First Quarter 2023 8,000,000 $ 0.005-0.04 3.75 Second Quarter 2023 15,000,000 $ 0.005-0.20 4.00 Third Quarter 2023 76,700,000 $ 0.005-0.10 4.25 Fourth Quarter 2023 60,243,000 $ 0.005 4.50 First Quarter 2024 34,600,000 $ 0.005 4.75 Second Quarter 2024 36,363,636 $ 0.005 5.00 Third Quarter 2028 3,000,000 $ 0.07 9.25 Second Quarter 2032 21,807,789 0.01-.0679 13.00 292,223,856 $ 0.001-3.74 |
Stock Compensation
Stock Compensation | 6 Months Ended |
Jun. 30, 2019 | |
Share-based Payment Arrangement [Abstract] | |
Stock Compensation | 9 Stock Compensation Shares Issued for Services During the quarters ended June 30, 2019 and 2018, the Company issued 0 and 375,000 shares of common stock respectively for consulting fees. The Company valued these shares at $0 and $125,899 respectively, based upon the fair value of the common stock at the dates of the agreements. The consulting fees are amortized over the contract periods, which are typically between 12 and 24 months. The amortization of prepaid services totaled $0 and $101,667 for the quarters ended June 30, 2019 and 2018. |
Income Taxes - Results of Opera
Income Taxes - Results of Operations | 6 Months Ended |
Jun. 30, 2019 | |
Income Tax Disclosure [Abstract] | |
Income Taxes - Results of Operations | 10. Income Taxes – Results of Operations There was no income tax expense reflected in the results of operations for the years ended June 30, 2019 and 2018 because the Company incurred a net loss in both years. On December 22, 2018, the President of the United States signed the Tax Cuts and Jobs Act (“U.S. Tax Reform”), which enacts a wide range of changes to the U.S. corporate income tax system. The impact of U.S. Tax Reform primarily represents the Company’s estimates of revaluing the Company’s U.S. deferred tax assets and liabilities based on the rates at which they are expected to be recognized in the future. For U.S. federal purposes the corporate statutory income tax rate was reduced from 35% to 21%, effective for the 2018 tax year. The Company has recognized no tax benefit for the losses generated for the periods through June 30, 2019. ASC Topic 740 requires that a valuation allowance be provided if it is more likely than not that some portion or all of a deferred tax asset will not be realized. The Company’s ability to realize the benefit of its deferred tax asset will depend on the generation of future taxable income. Because the Company has yet to recognize revenue, we believe that the full valuation allowance should be provided. Our effective tax rate for fiscal years 2019 and 2018 was 0%. Our tax rate can be affected by recurring items, such as tax rates in foreign jurisdictions and the relative amount of income we earn in jurisdictions. It may also be affected by discrete items that may occur in any given year but are not consistent from year to year. |
Licenses and Supply Agreements
Licenses and Supply Agreements | 6 Months Ended |
Jun. 30, 2019 | |
Licenses And Supply Agreements | |
Licenses and Supply Agreements | 11. Licenses and Supply Agreements Patent and Subsidiary Acquisition In December 2014, the Company transferred to Cytocom certain of its rights, title and interest in or relating to intellectual property (i) patents, patent applications, and all divisional, continuations and continuations-in-part thereof, together with all reissues, reexaminations, renewals and extensions thereof and all rights to obtain such divisionals, continuations and continuations-in-part, reissues, reexaminations, renewals and extensions, and all utility models and statutory invention registrations and any other such analogous rights, (ii) trademarks, service marks, Internet domain names, trade dress, trade styles, logos, trade names, services names, brand names, corporate names, assumed business names and general intangibles and other source identifiers of a like nature, together with the goodwill associated with any of the foregoing, and all registrations and applications for registrations thereof, together with all renewals and extensions thereof and all rights to obtain such renewals and extensions, (iii) copyrights, mask work rights, database and design rights, moral rights and rights in Internet websites, whether registered or unregistered and whether published or unpublished, all registrations and recordings thereof and all applications in connection therewith, together with all renewals, continuations, reversions and extensions thereof and all rights to obtain such renewals, continuations, reversions and extensions, and (iv) confidential and proprietary information, including, trade secrets and know-how. Cytocom licensed back to the Company a perpetual, non-exclusive, royalty-free right and license to use the assigned intellectual property for veterinary indications and for the marketing rights to emerging markets, access to all clinical data, use of the formulation for LDN and MENK. The Original Agreement also granted the Company rights to market Lodonal™ and Met-Enkephalin (“MENK”) in “Emerging Markets,” which included all countries excluding Canada, Italy, Japan, France, Germany, United Kingdom, European Community and the United States. Pursuant to the Original Agreement, the Company was required to pay Cytocom a 5% royalty on all sales all ongoing drug development and fees due in connection with the underlying patents until such time as Cytocom was funded. On May 1, 2018, the Company entered into an amended and restated licensing agreement (the “Restated Agreement”) with Cytocom. The Restated Agreement restates the licensing arrangement between the Company and Cytocom as provided by the Original Agreement. The Restated Agreement grants the Company distribution and marketing rights for Lodonal™ and MENK for humans in Emerging Markets. In addition, the Company has been granted the rights to distribute and market Lodonal™ and MENK for animal use in the United States. The royalty due to Cytocom has been reduced from 5% to 1% of sales and the Company no longer has any ongoing obligations to pay for the cost in connection with the assets of Cytocom. |
Commitments and Contingencies
Commitments and Contingencies | 6 Months Ended |
Jun. 30, 2019 | |
Commitments and Contingencies Disclosure [Abstract] | |
Commitments and Contingencies | 12. Commitments and Contingencies Distribution Agreements in Nigeria In October 2013, the Company announced the signing of a Distribution Agreement with AHAR Pharma, a Nigerian company, to market Lodonal™, in Nigeria for the treatment of autoimmune diseases and cancer. AHAR intends to distribute Lodonal™ through a local distributor network, an Internet client base and directly to hospitals, pharmacists and doctors in Nigeria. The first deliveries under the agreement took place in February 2018. Under the original agreement, the Company is obligated to provide delivery of an initial supply of between 1 million and 1.5 million doses of Lodonal™ product to cover AHAR Pharma’s first-year purchase commitment. Due to the fact that AHAR Pharma failed to meet its contractual purchase obligations, the Company formally issued notice of default under the agreement. On April 18, 2018, AHAR Pharma transferred its rights under the Distribution Agreement to Fidson Healthcare Plc (“Fidson”), and Fidson signed an exclusive distribution agreement with the Company to distribute Lodonal™. There were no shipments under this agreement in the first half of 2019. Contract Manufacturing Agreements On October 25, 2016, the Company and Acromax Dominicana, SA (“Acromax”), which is based in the Dominican Republic, entered into a contract for manufacturing of LDN tablets, capsules and/or creams (“Agreement”). Subject to the terms and conditions of the Agreement, Acromax will obtain all necessary licenses and permits to carry out the manufacturing and packaging of LDN in exchange for a fixed fee per tablet plus an additional fee for packaging, shipping and customs clearance. The Agreement has an initial term of five years unless terminated by either party in accordance with the terms. Operating Leases At June 30, 2019, the Company was a party to an agreement to lease office space in Orlando, Florida. Rental expense for the three months ended June 30, 2019 and 2018 was $2,162 and $4,451 respectively. |
Subsequent Events
Subsequent Events | 6 Months Ended |
Jun. 30, 2019 | |
Subsequent Events [Abstract] | |
Subsequent Events | 13. Subsequent Events None. |
Summary of Significant Accoun_2
Summary of Significant Accounting Policies (Policies) | 6 Months Ended |
Jun. 30, 2019 | |
Accounting Policies [Abstract] | |
Basis of Presentation | Basis of Presentation The consolidated financial statements included herein have been prepared by the Company, without audit, pursuant to the rules and regulations of the Securities and Exchange Commission. Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. generally accepted accounting principles have been omitted. However, in the opinion of management, all adjustments (which include only normal recurring adjustments, unless otherwise indicated) necessary to present fairly the financial position and results of operations for the periods presented have been made. The results for interim periods are not necessarily indicative of trends or of results to be expected for the full year. These financial statements should be read in conjunction with the financial statements of the Company for the year ended December 31, 2018 (including the notes thereto) set forth in Form 10- K. We have identified the policies below as critical to our business operations and the understanding of its results of operations. The Company’s senior management has reviewed these critical accounting policies and related disclosures with the Company’s Board of Directors. The impact and any associated risks related to these policies on our business operations are discussed throughout this section where such policies affect our reported and expected financial results. The Company qualifies as an “emerging growth company” as defined in Section 101 of the Jumpstart our Business Startups Act (“JOBS Act”) as we do not have more than $1,000,000,000 in annual gross revenue for the year ended December 31, 2018. We are electing to use the extended transition period for complying with new or revised accounting standards under Section 102(b)(1) of the JOBS Act. |
Non-Controlling Interest in Consolidated Subsidiaries | Non-Controlling Interest in Consolidated Subsidiaries Prior to May 1, 2018, the Company consolidated Cytocom. On May 1, 2018, the Company entered into an amended and restated licensing agreement (the “Restated Agreement”) with Cytocom, Inc., in accordance with which the Company no longer has any ongoing obligations to pay for costs in connection with the assets of Cytocom. On June 4, 2018, the Company and Cytocom entered into a Stock Purchase Agreement (the “Stock Agreement”). Pursuant to the Stock Agreement, the Company cancelled approximately $4,000,000 of debt owed to it by Cytocom in exchange for ten percent (10%) of the issued and outstanding common stock of Cytocom, as calculated on a fully diluted basis on June 4, 2018. At June 30, 2019, the Company’s equity interest in Cytocom stood at 15.26% of Cytocom’s common stock issued and outstanding. Accordingly, the Company deconsolidated Cytocom as of May 1, 2018, and accounts for its retained interest in Cytocom under the equity method of accounting, with the Company’s share of Cytocom’s earnings recorded in “loss from equity method investment” in the consolidated statements of operations. As the balance of the Company’s investment in Cytocom has been $0 since December 31, 2018, no losses have been recognized during the quarter ended June 30, 2019. |
Revenue Recognition | Revenue Recognition We recognize revenue on sales to customers and distributors upon satisfaction of our performance obligations when the goods are shipped. For consignment sales, we recognize revenue when the goods are pulled from consignment inventory. Sales of LodonalTM pills or capsules product are included in revenue when production is sold to a customer in fulfillment of performance obligations under the terms of agreed contracts. Performance obligations primarily comprise delivery of product at a delivery point, as negotiated within each contract. Each quantity of product sold is separately identifiable and represents a distinct performance obligation to which the transaction price is allocated. Performance obligations are satisfied at a point in time once control of the product has been transferred to the customer. The Company considers a variety of facts and circumstances in assessing the point of control transfer, including but not limited to: whether the purchaser can direct the use of the product, the transfer of significant risks and rewards, the Company’s right to payment, and transfer of legal title. In each case, the time between delivery and when payments are due is not significant. |
Leases | Leases In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842). This standard requires all leases that have a term of over 12 months to be recognized on the balance sheet with the liability for lease payments and ‘the corresponding right-of-use asset initially measured at the present value of amounts expected to be paid over the term. Recognition of the costs of these leases on the income statement will be dependent upon their classification as either an operating or a financing lease. Costs of an operating lease will continue to be recognized as a single operating expense on a straight-line basis over the lease term. Costs for a financing lease will be disaggregated and recognized as both an operating expense (for the amortization of the right-of-use asset) and interest expense (for interest on the lease liability). On January 1, 2019, the Company applied ASU 842 on a modified retrospective basis to leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements. At June 30, 2019, we had no leases that fall within the scope of this standard. Accordingly, the standard has no impact on our consolidated financial position or our results of operations. |
Use of Estimates | Use of Estimates The preparation of the Company’s financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from such estimates. |
Cash, Cash Equivalents, and Short-Term Investments | Cash, Cash Equivalents, and Short-Term Investments The Company considers all highly liquid investments with original maturities at the date of purchase of three months or less to be cash equivalents. Cash and cash equivalents include bank demand deposits, marketable securities with maturities of three months or less at purchase, and money market funds that invest primarily in certificates of deposits, commercial paper and U.S. government and U.S. government agency obligations. Cash equivalents are reported at fair value . |
Concentration of Credit Risk | Concentration of Credit Risk Financial instruments that potentially subject the Company to concentrations of credit risk are primarily cash and cash equivalents. The Company is exposed to credit risk, subject to federal deposit insurance, in the event of a default by the financial institutions holding its cash and cash equivalents to the extent of amounts recorded on the condensed consolidated balance sheets. The cash accounts are insured by the Federal Deposit Insurance Corporation up to $250,000. At June 30, 2019, the Company has no cash balances in excess of insured limits. |
Segment and Geographic Information | Segment and Geographic Information Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company views its operations and manages its business in one operating segment and does not segment the business for internal reporting or decision making. |
Fair Value of Financial Instruments | Fair Value of Financial Instruments In accordance with the reporting requirements of Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) Topic 825, “Financial Instruments”, the Company calculates the fair value of its assets and liabilities which qualify as financial instruments under this standard and includes this additional information in the notes to the financial statements when the fair value is different than the carrying value of those financial instruments. Cash, cash equivalents and accounts payable are accounted for at cost which approximates fair value due to the relatively short maturity of these instruments. The carrying value of notes payable also approximate fair value since they bear market rates of interest and other terms. None of these instruments are held for trading purposes. |
Derivative Financial Instruments | Derivative Financial Instruments FASB ASC 820, Fair Value Measurements |
Inventory | Inventory Inventories comprise finished product, raw materials and materials used for packaging. Inventories are stated at the lower of cost or market with cost based on the first-in, first-out (FIFO) method. Inventory that can be used in either the production of clinical or commercial products is expensed as research and development costs when identified for use in a clinical trials or clinical manufacturing campaigns. Inventory used in marketing activities is charged to selling, general and administrative expense. Inventory as of June 30, 2019 was valued at $0, a decrease of $158,648 or 100% from the inventory balance at the end of June 2018, as the inventory was deemed obsolete and written off as a result. |
Fixed Assets | Fixed Assets Fixed assets are stated at cost, less accumulated depreciation. Depreciation is determined on a straight-line basis over the estimated useful lives of the assets, which generally range from three to five years. Maintenance and repairs are charged against expense as incurred. Depreciation expense for the quarters ended June 30, 2019 and June 30, 2018 was $691 and $433, respectively. |
Impairment of Long-Lived Assets | Impairment of Long-Lived Assets The Company evaluates long-lived assets for impairment whenever events or change in circumstances indicate that the carrying amount of an asset may not be recoverable as prescribed by ASC Topic 360-10-05, “Property, Plant and Equipment.” If the carrying amount of the asset, including any intangible assets associated with that asset, exceeds its estimated undiscounted net cash flow, before interest, the Company will recognize an impairment loss equal to the difference between its carrying amount and its estimated fair value. |
Research and Development Costs | Research and Development Costs Research and development costs are charged to expense as incurred and are typically comprised of salaries and benefits, pre-clinical studies, clinical trial activities, drug development and manufacturing, fees paid to consultants and other entities that conduct certain research and development activities on the Company’s behalf and third-party service fees, including clinical research organizations and investigative sites. Costs for certain development activities, such as clinical trials are recognized based on an evaluation of the progress to completion of specific tasks using data such as patient enrollment, clinical site activations, or information provided by vendors on their actual costs incurred. Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected in the financial statements as operating expenses. |
Income Taxes | Income Taxes The Company follows ASC Topic 740, Income Taxes, which requires recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred tax assets and liabilities are based on the differences between the financial statements and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Deferred tax assets are reduced by a valuation allowance to the extent management concludes it is more likely than not that the asset will not be realized. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The standard addresses the determination of whether tax benefits claimed or expected to be claimed on a tax return should be recorded in the financial statements. Under ASC Topic 740, the Company may recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the tax authorities, based on the technical merits of the position. The tax benefits recognized in the financial statements from such a position should be measured based on the largest benefit that has a greater than fifty percent likelihood of being realized upon ultimate settlement. ASC Topic 740 also provides guidance on de-recognition, classification, interest and penalties on income taxes, accounting in interim periods and requires increased disclosures. At the date of adoption, and as of June 30, 2019 and 2018, the Company does not have a liability for unrecognized tax uncertainties. The Company’s policy is to record interest and penalties on uncertain tax positions as income tax expense. As of June 30, 2019, and 2018, the Company has not accrued any interest or penalties related to uncertain tax positions. |
Stock-Based Compensation and Issuance of Stock for Non-Cash Consideration | Stock-Based Compensation and Issuance of Stock for Non-Cash Consideration The Company measures and recognizes compensation expense for all share-based payment awards made to employees and directors, including employee stock options, based on estimated fair values equaling either the market value of the shares issued or the value of consideration received, whichever is more readily determinable. The majority of the non-cash consideration pertains to services rendered by consultants and others and has been valued at the fair value of the Company’s common stock at the date of the agreement. The Company’s accounting policy for equity instruments issued to consultants and vendors in exchange for goods and services follows the provisions of ASC Topic 505-50, “Equity-Based Payments to Non-Employees.” The measurement date for the fair value of the equity instruments issued is determined at the earlier of (i) the date at which a commitment for performance by the consultant or vendor is reached or (ii) the date at which the consultant or vendor’s performance is complete. |
Net Loss Per Share of Common Stock | Net Loss per Share of Common Stock Basic net loss per share is calculated by dividing the net loss attributable to common stockholders by the weighted average number of common shares outstanding for the period, without consideration for common stock equivalents. Diluted net loss per share is calculated by dividing the net loss by the weighted-average number of common share equivalents outstanding for the period determined using the treasury-stock method and the if-converted method. Dilutive common stock equivalents are comprised of common stock purchase warrants and options outstanding. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding due to the Company’s net loss position The Company’s potential dilutive securities which include warrants (as described in Note 8 to the Financial Statements – “Capital Structure – Common Stock and Common Stock Purchase Warrants”) and convertible debt (as described in Note 6 to the Financial Statements – “Notes Payable”), have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss per share. |
Recent Accounting Standards | Recent Accounting Standards During the quarter ended June 30, 2019, there were several new accounting pronouncements issued by the Financial Accounting Standards Board. Each of these pronouncements, as applicable, has been or will be adopted by the Company. Management does not believe the adoption of any of these accounting pronouncements has had or will have a material impact on the Company’s consolidated financial statements. |
Fixed Assets (Tables)
Fixed Assets (Tables) | 6 Months Ended |
Jun. 30, 2019 | |
Fixed Assets: | |
Schedule of Fixed Assets | June 30, 2019 December 31, 2018 Fixed Assets: Computer equipment $ 13,213 $ 13,213 Less accumulated depreciation (11,138 ) (10,447 ) Fixed assets, net $ 2,075 $ 2,766 |
Accrued Liabilities (Tables)
Accrued Liabilities (Tables) | 6 Months Ended |
Jun. 30, 2019 | |
Payables and Accruals [Abstract] | |
Schedule of Accrued Liabilities | Accrued expenses and other liabilities consist of the following: June 30, 2019 December 31, 2018 Accrued payroll to officers and others $ 2,819,551 $ 2,010,570 Accrued interest and penalties – notes payable 959,412 877,571 Estimated legal settlements 136,057 136,057 Other accrued liabilities - 15,512 Total accrued expenses and other liabilities $ 3,915,020 $ 3,039,710 |
Notes Payable (Tables)
Notes Payable (Tables) | 6 Months Ended |
Jun. 30, 2019 | |
Debt Disclosure [Abstract] | |
Schedule of Notes Payable | Notes payable consist of the following: June 30, 2019 December 31, 2018 Promissory note issued July 29, 2014 to Ira Gaines. In 2016, the maturity date on the note was extended to December 1, 2017. As of June 30, 2019, the note is in default. The note earns interest at a rate of 18% per annum. $ 100,000 $ 100,000 Promissory notes issued between November 26, 2014 and December 31, 2015, to raise up to $2,000,000 in debt. Lenders earn interest at a rate of 10% per annum, plus a pro-rata share of two percent of the Company’s gross receipts for sales of IRT-103-LDN in perpetuity. Notes will be repaid in 36 monthly installments of principal and interest commencing no later than October 15, 2015. These notes were in default at June 30, 2019, as the Company was unable to pay installments on their due dates. 286,000 286,000 Promissory notes issued between May 1, 2015 and December 31, 2016 and maturing between June 14, 2015 and December 1, 2017. Lenders on loans aggregating $375,994 earn interest at rates between 2% and 18% per annum. On loans aggregating $100,000, interest is payable in a fixed amount not tied to a specific interest rate. The Company was unable to repay the notes at maturity and at June 30, 2019 the note was in default. 725,994 725,994 Promissory notes issued to an officer of the Company effective November 3, 2015 and maturing November 3, 2016 for settlement of accrued payroll, bearing interest at 10% per annum and including a stock conversion feature. The Company was unable to repay the note at maturity and at June 30, 2019 the note was in default. 97,737 97,737 Promissory notes issued between July 1, 2016 and December 31, 2016. Lenders earn interest at 2% per annum. The notes mature on December 31, 2017, and at June 30, 2019 the notes were in default. 206,000 206,000 Promissory notes aggregating $1,350,000 issued in the fourth quarter 2016. The notes accrue interest at 2% per annum and mature between November 1, 2017 and December 31, 2017. As June 30, 2019, the notes were in default. 1,354,000 1,354,000 Promissory notes aggregating $500,000 issued in the first quarter of 2017. The notes accrue interest at 2% per annum and mature between January 12, 2018 and June 30, 2018. At June 30, 2019, the notes were in default. 500,000 500,000 Promissory notes issued January 25, 2017. The lenders earn interest at 7% per month. The notes mature on July 5, 2017, and at June 30, 2019 the notes were in default. 50,000 50,000 Promissory notes aggregating $300,000 issued in the second quarter of 2017. The notes accrue interest at 2% per annum and mature between April 3, 2018 and May 31, 2018. At June 30, 2019, the notes were in default. 300,000 300,000 Promissory notes aggregating $191,800 issued in the third quarter of 2017. The notes accrue interest at 2% per annum and mature between June 16, 2018 and December 31, 2018. At June 30, 2019, the notes were in default. 191,800 191,800 Promissory note for $425,000 issued in October 2017 with an original issue discount of $70,000. The note is in default, giving the holder an option to convert the note to stock using the lowest value of the Company’s common stock 25 days prior to the conversion. In 2018, The defaults also resulted in certain penalties, as a result of which the principal amount of the note outstanding at June 30, 2019 had increased to $454,032. $49,943 of accrued interest owed on the note has been converted to stock. The Company has accrued a $908,873 derivative liability for the remaining conversion right. 454,032 455,122 Promissory notes aggregating $105,500 issued in the fourth quarter of 2017. The notes accrue interest at 2% per annum. At June 30, 2019, the notes were in default. 105,500 105,500 Promissory notes aggregating $47,975 issued in the first quarter of 2018. The notes accrue interest at 2% per annum and mature between May 2018 and January 2019. At June 30, 2019, the notes were in default. 47,975 47,975 Promissory notes aggregating $125,000 issued in the first quarter of 2018. The notes accrue interest between 2% and 12% per annum and mature between April 2018 and June 2018. These notes include warrants between 5,000,000 and 20,000,000 shares with an exercise price of $0.0005. At June 30, 2019 the notes were in default 125,000 125,000 Promissory notes aggregating $65,000 issued in the second quarter of 2018. The notes accrue interest between 2% per annum and mature between July 2018 and October 2018. These notes include warrants between 1,000,000 and 5,000,000 shares with an exercise price of $0.005. At June 30, 2019 the notes were in default 65,000 65,000 Promissory notes aggregating $193,000 issued in the third quarter of 2018. The notes accrue interest at 2% per annum and mature between November 2018 and January 2019. These notes include warrants between 600,000 and 5,000,000 shares with an exercise price of $0.005. At June 30, 2019, $103,000 of these notes were in default. 193,000 193,000 Promissory notes aggregating $533,855 issued in the fourth quarter of 2018. The notes accrue interest from 2% to 3.5% per annum and mature between February 2019 and December 2019. These notes include warrants between 200,000 and 39,500,000 shares with an exercise price of $0.005 to $0.04. At June 30, 2019, $479,000 of these notes were in default. 533,855 533,855 Promissory note for $23,000 issued in the first quarter of 2019. The note accrues interest at 2% per annum and matures during July 2019. The note includes warrants for 4,600,000 shares with an exercise price of $0.005. At June 30, 2019, the note was in default. 23,000 - Promissory note for $231,478 issued in the first quarter of 2019. The note accrues interest at 6% per annum and matures in February 2020. 231,478 - Promissory notes aggregating $50,000 issued in the second quarter of 2019. The notes accrue interest at 2% per annum and mature between July and September 2019. These notes include warrants for 10,000,000 shares with an exercise price of $0.005. 50,000 - Less: Original issue discount on notes payable and warrants issued with notes. (59,238 ) (149,256 ) Total $ 5,581,133 $ 5,187,727 |
Derivative Liabilities (Tables)
Derivative Liabilities (Tables) | 6 Months Ended |
Jun. 30, 2019 | |
Derivative Instruments and Hedging Activities Disclosure [Abstract] | |
Schedule of Estimated Fair Value of Derivative Liability Valuation Assumptions | The Company estimated the fair value of the derivative liability using the Black-Scholes option pricing model using the following key assumption during the quarter June 30, 2019: Three months ended June 30, 2019 Volatility 209.43 % Risk-free interest rate 1.92 % Expected dividends - % Expected term 1 year |
Schedule of Valuation of Financial Instruments | The following schedule summarizes the valuation of financial instruments at fair value in the balance sheet as of June 30, 2019: Fair Value Measurements as of June 30, 2019 Level 1 Level 2 Level 3 Assets Total assets - - - Liabilities Conversion option derivative liability $ - $ - $ 908,873 Total liabilities $ - $ - $ 908,873 |
Schedule of Reconciliation of Changes in the Fair Value of Derivative Liabilities | The following table set forth a reconciliation of changes in the fair value of derivative liabilities classified as Level 3 in the fair value hierarchy: Significant Unobservable Input (Level 3) Beginning balance $ 786,706 Change in fair value 157,492 Partial settlements of liability (35,325 ) Ending balance $ 908,873 |
Capital Structure - Common St_2
Capital Structure - Common Stock and Stock Purchase Warrants (Tables) | 6 Months Ended |
Jun. 30, 2019 | |
Equity [Abstract] | |
Schedule of Outstanding Stock Warrants | Following is a summary of outstanding stock warrants at, and activity during the six months ended, June 30, 2019: Number of Shares Exercise Price Weighted Average Price Warrants as of December 31, 2018 281,782,856 $ 0.001-3.74 $ 0.09 Issued in 2019 14,600,000 $ .005 $ 0.01 Expired and forfeited (4,159,000 ) $ 0.00-2.00 $ 1.25 Exercised - $ - $ - Warrants as of June 30, 2019 292,233,856 $ 0.001-3.74 $ 0.07 |
Summary of Outstanding Warrants | Summary of outstanding warrants as of June 30, 2019: Expiration Date Number of Shares Exercise Price Remaining Life (years) Third Quarter 2019 260,000 $ 0.07-0.23 0.25 Fourth Quarter 2019 23,222,726 $ 0.50-1.50 0.50 Second Quarter 2020 300,000 $ 0.50 1.00 Fourth Quarter 2020 1,000,000 $ 0.20 1.50 First Quarter 2021 12,600,000 $ 0.20 1.75 Second Quarter 2021 5,812,252 $ 0.01408-0.20 2.00 Third Quarter 2021 5,166,667 $ 0.03-0.20 2.25 Fourth Quarter 2021 300,000 $ 0.10 2.50 Second Quarter 2022 1,750,000 $ 0.15 3.00 Third Quarter 2022 2,650,000 $ 0.05-0.10 3.25 Fourth Quarter 2022 9,811,422 $ 0.08-0.29 3.50 First Quarter 2023 8,000,000 $ 0.005-0.04 3.75 Second Quarter 2023 15,000,000 $ 0.005-0.20 4.00 Third Quarter 2023 76,700,000 $ 0.005-0.10 4.25 Fourth Quarter 2023 60,243,000 $ 0.005 4.50 First Quarter 2024 34,600,000 $ 0.005 4.75 Second Quarter 2024 36,363,636 $ 0.005 5.00 Third Quarter 2028 3,000,000 $ 0.07 9.25 Second Quarter 2032 21,807,789 0.01-.0679 13.00 292,223,856 $ 0.001-3.74 |
Organization and Description _2
Organization and Description of Business (Details Narrative) - USD ($) | Jun. 04, 2018 | May 01, 2018 | Dec. 08, 2014 | Dec. 31, 2014 | Mar. 31, 2014 | Jun. 30, 2019 | Jun. 30, 2018 | Jun. 30, 2019 | Jun. 30, 2018 | Apr. 08, 2019 | Dec. 31, 2018 | Dec. 31, 2017 |
Net loss attributable to common shareholders | $ 824,709 | $ 4,018,514 | $ 1,534,118 | $ 4,629,167 | ||||||||
Cash and cash equivalents used in operating activities | (15,538) | 870,087 | ||||||||||
Stockholder's deficit | $ 12,529,322 | $ 9,607,478 | $ 12,529,322 | $ 9,607,478 | $ 11,250,638 | $ 11,103,386 | ||||||
Cytocom Inc., [Member] | ||||||||||||
Ownership percentage | 15.26% | 15.26% | ||||||||||
Licensing Agreement [Member] | ||||||||||||
Ownership percentage | 15.57% | |||||||||||
Cytocom Inc., [Member] | ||||||||||||
Royalty percentage | 5.00% | |||||||||||
Cytocom Inc., [Member] | Original Agreement [Member] | ||||||||||||
Number of common stock issued | 140,100,000 | |||||||||||
Ownership percentage | 55.30% | |||||||||||
Cytocom Inc., [Member] | Restated Agreement [Member] | Minimum [Member] | ||||||||||||
Royalty percentage | 1.00% | |||||||||||
Cytocom Inc., [Member] | Restated Agreement [Member] | Maximum [Member] | ||||||||||||
Royalty percentage | 5.00% | |||||||||||
Cytocom Inc., [Member] | Stock Purchase Agreement [Member] | ||||||||||||
Amount of debt converted into common stock | $ 4,000,000 | |||||||||||
Percentage of common stock issued in exchange of debt | 10.00% | |||||||||||
Cytocom Inc., [Member] | Shareholders [Member] | ||||||||||||
Number of common stock issued | 113,242,522 | |||||||||||
Irish Limited Liability [Member] | ||||||||||||
Percentage of low corporate income tax rate | 12.50% |
Summary of Significant Accoun_3
Summary of Significant Accounting Policies (Details Narrative) | Jun. 04, 2018USD ($) | Jun. 30, 2019USD ($)Segment | Jun. 30, 2018USD ($) | Dec. 31, 2018USD ($) | Mar. 31, 2018USD ($) |
Maximum of annual gross revenue | $ 1,000,000,000 | ||||
Federal deposit insurance corporation value | $ 250,000 | ||||
Number of operating segment | Segment | 1 | ||||
Inventory | 82,801 | ||||
Decrease in inventory | $ (82,801) | $ (19,450) | |||
Percentage on decrease in inventory | 100.00% | ||||
Depreciation expense | $ 691 | $ 867 | |||
Accrued interest or penalties related to uncertain tax positions | |||||
Property and Equipment [Member] | Minimum [Member] | |||||
Property and equipment useful lives | 3 years | ||||
Property and Equipment [Member] | Maximum [Member] | |||||
Property and equipment useful lives | 5 years | ||||
Cytocom Inc., [Member] | |||||
Percentage of equity ownership | 15.26% | ||||
Cytocom Inc., [Member] | |||||
Investment | $ 0 | ||||
Cytocom Inc., [Member] | Stock Purchase Agreement [Member] | |||||
Amount of debt converted into common stock | $ 4,000,000 | ||||
Percentage of common stock issued in exchange of debt | 10.00% |
Fixed Assets - Schedule of Fixe
Fixed Assets - Schedule of Fixed Assets (Details) - USD ($) | Jun. 30, 2019 | Dec. 31, 2018 |
Fixed Assets: | ||
Computer equipment | $ 13,213 | $ 13,213 |
Less accumulated depreciation | (11,138) | (10,477) |
Fixed assets, net | $ 2,075 | $ 2,766 |
Investments_ Deconsolidation _2
Investments: Deconsolidation of Cytocom (Details Narrative) - USD ($) | 6 Months Ended | ||
Jun. 30, 2019 | Dec. 31, 2018 | May 01, 2018 | |
Equity method investments | |||
Cytocom Inc., [Member] | |||
Equity method investments | $ 1,189 | ||
Loss on investment | $ 0 |
Accrued Liabilities - Schedule
Accrued Liabilities - Schedule of Accrued Liabilities (Details) - USD ($) | Jun. 30, 2019 | Dec. 31, 2018 |
Payables and Accruals [Abstract] | ||
Accrued payroll to officers and others | $ 2,819,551 | $ 2,010,570 |
Accrued interest and penalties - notes payable | 959,412 | 877,571 |
Estimated legal settlements | 136,057 | 136,057 |
Other accrued liabilities | 15,512 | |
Total accrued expenses and other liabilities | $ 3,915,020 | $ 3,039,710 |
Notes Payable (Details Narrativ
Notes Payable (Details Narrative) - USD ($) | 6 Months Ended | |
Jun. 30, 2019 | Jun. 30, 2018 | |
Accrued unpaid interest and default penalties | $ 959,412 | $ 774,793 |
Issuance of common stock for conversion of debt | $ 62,434 | $ 451,414 |
Promissory Notes [Member] | ||
Issuance of common stock for conversion of debt, shares | 8,607,200 | |
Issuance of common stock for conversion of debt | $ 451,414 |
Notes Payable - Schedule of Not
Notes Payable - Schedule of Notes Payable (Details) - USD ($) | Jun. 30, 2019 | Mar. 31, 2019 | Dec. 31, 2018 | Oct. 31, 2017 |
Total | $ 5,581,133 | $ 5,187,727 | ||
Less: Original issue discounts on notes payable and warrants issued with notes | (59,238) | (149,256) | ||
Notes Payable One [Member] | ||||
Total | 100,000 | 100,000 | ||
Notes Payable Two [Member] | ||||
Total | 286,000 | 286,000 | ||
Notes Payable Three [Member] | ||||
Total | 725,994 | 725,994 | ||
Notes Payable Four [Member] | ||||
Total | 97,737 | 97,737 | ||
Notes Payable Five [Member] | ||||
Total | 206,000 | 206,000 | ||
Notes Payable Six [Member] | ||||
Total | 1,354,000 | 1,354,000 | ||
Notes Payable Seven [Member] | ||||
Total | 500,000 | 500,000 | ||
Notes Payable Eight [Member] | ||||
Total | 50,000 | 50,000 | ||
Notes Payable Nine [Member] | ||||
Total | 300,000 | 300,000 | ||
Notes Payable Ten [Member] | ||||
Total | 191,800 | 191,800 | ||
Notes Payable Eleven [Member] | ||||
Total | 454,032 | 455,122 | ||
Less: Original issue discounts on notes payable and warrants issued with notes | $ (70,000) | |||
Notes Payable Twelve [Member] | ||||
Total | 105,500 | 105,500 | ||
Notes Payable Thirteen [Member] | ||||
Total | 47,975 | 47,975 | ||
Notes Payable Fourteen [Member] | ||||
Total | 125,000 | 125,000 | ||
Notes Payable Fifteen [Member] | ||||
Total | 65,000 | 65,000 | ||
Notes Payable Sixteen [Member] | ||||
Total | 193,000 | 193,000 | ||
Notes Payable Seventeen [Member] | ||||
Total | 533,855 | 533,855 | ||
Notes Payable Eighteen [Member] | ||||
Total | $ 23,000 | |||
Notes Payable Nineteen [Member] | ||||
Total | 231,478 | |||
Notes Payable Twenty [Member] | ||||
Total | $ 50,000 |
Notes Payable - Schedule of N_2
Notes Payable - Schedule of Notes Payable (Details) (Parenthetical) | Jan. 25, 2017 | Nov. 03, 2015 | Jul. 29, 2014 | Jun. 30, 2019USD ($)$ / sharesshares | Dec. 31, 2018USD ($)$ / sharesshares | Sep. 30, 2018USD ($)$ / sharesshares | Jun. 30, 2018USD ($)$ / sharesshares | Mar. 31, 2018USD ($)$ / sharesshares | Sep. 30, 2017USD ($) | Jun. 30, 2017USD ($) | Dec. 31, 2016USD ($) | Jun. 30, 2019USD ($)$ / sharesshares | Jun. 30, 2017USD ($) | Dec. 31, 2016USD ($) | Dec. 31, 2015USD ($)Installments | Dec. 31, 2016USD ($) | Mar. 31, 2019USD ($)$ / sharesshares | Dec. 31, 2017USD ($) | Oct. 31, 2017USD ($) |
Accrued interest | $ 959,412 | $ 877,571 | $ 959,412 | ||||||||||||||||
Original issuance discount | 59,238 | $ 149,256 | 59,238 | ||||||||||||||||
Notes Payable Two [Member] | |||||||||||||||||||
Percentage of interest rate per annum | 10.00% | ||||||||||||||||||
Number of installments, months | Installments | 36 | ||||||||||||||||||
Notes Payable Two [Member] | Maximum [Member] | |||||||||||||||||||
Maximum amount raise in debt | $ 2,000,000 | ||||||||||||||||||
Notes Payable Four [Member] | |||||||||||||||||||
Note matures date | Nov. 3, 2016 | ||||||||||||||||||
Percentage of interest rate per annum | 10.00% | ||||||||||||||||||
Notes Payable Five [Member] | Lenders [Member] | |||||||||||||||||||
Note matures date | Dec. 31, 2017 | ||||||||||||||||||
Percentage of interest rate per annum | 2.00% | 2.00% | 2.00% | ||||||||||||||||
Notes Payable Six [Member] | |||||||||||||||||||
Percentage of interest rate per annum | 2.00% | 2.00% | 2.00% | ||||||||||||||||
Debt instrument maturity date description | November 1, 2017 and December 31, 2017 | ||||||||||||||||||
Notes aggregating default amount | $ 1,350,000 | $ 1,350,000 | $ 1,350,000 | ||||||||||||||||
Notes Payable Seven [Member] | |||||||||||||||||||
Percentage of interest rate per annum | 2.00% | 2.00% | |||||||||||||||||
Debt instrument maturity date description | January 12, 2018 and June 30, 2018 | ||||||||||||||||||
Notes aggregating default amount | $ 500,000 | $ 500,000 | |||||||||||||||||
Notes Payable Nine [Member] | |||||||||||||||||||
Percentage of interest rate per annum | 2.00% | 2.00% | |||||||||||||||||
Debt instrument maturity date description | April 3, 2018 and May 31, 2018 | ||||||||||||||||||
Notes aggregating default amount | $ 300,000 | $ 300,000 | |||||||||||||||||
Notes Payable Ten [Member] | |||||||||||||||||||
Percentage of interest rate per annum | 2.00% | ||||||||||||||||||
Debt instrument maturity date description | June 16, 2018 and December 31, 2018 | ||||||||||||||||||
Notes aggregating default amount | $ 191,800 | ||||||||||||||||||
Notes Payable Eleven [Member] | |||||||||||||||||||
Maximum amount raise in debt | 454,032 | 454,032 | |||||||||||||||||
Accrued interest | 49,943 | 49,943 | |||||||||||||||||
Notes aggregating default amount | $ 425,000 | ||||||||||||||||||
Original issuance discount | $ 70,000 | ||||||||||||||||||
Derivative liability | 908,873 | 908,873 | |||||||||||||||||
Notes Payable Twelve [Member] | |||||||||||||||||||
Percentage of interest rate per annum | 2.00% | ||||||||||||||||||
Notes aggregating default amount | $ 105,500 | ||||||||||||||||||
Notes Payable Thirteen [Member] | |||||||||||||||||||
Percentage of interest rate per annum | 2.00% | ||||||||||||||||||
Debt instrument maturity date description | May 2018 and January 2019 | ||||||||||||||||||
Notes aggregating default amount | $ 47,975 | ||||||||||||||||||
Notes Payable Fourteen [Member] | |||||||||||||||||||
Debt instrument maturity date description | April 2018 and June 2018 | ||||||||||||||||||
Notes aggregating default amount | $ 125,000 | ||||||||||||||||||
Warrant exercise price per share | $ / shares | $ 0.0005 | ||||||||||||||||||
Notes Payable Fourteen [Member] | Maximum [Member] | |||||||||||||||||||
Percentage of interest rate per annum | 12.00% | ||||||||||||||||||
Number of warrants | shares | 20,000,000 | ||||||||||||||||||
Notes Payable Fourteen [Member] | Minimum [Member] | |||||||||||||||||||
Percentage of interest rate per annum | 2.00% | ||||||||||||||||||
Number of warrants | shares | 5,000,000 | ||||||||||||||||||
Notes Payable Fifteen [Member] | |||||||||||||||||||
Percentage of interest rate per annum | 2.00% | ||||||||||||||||||
Debt instrument maturity date description | July 2018 and October 2018 | ||||||||||||||||||
Notes aggregating default amount | $ 65,000 | ||||||||||||||||||
Warrant exercise price per share | $ / shares | $ 0.005 | ||||||||||||||||||
Notes Payable Fifteen [Member] | Maximum [Member] | |||||||||||||||||||
Number of warrants | shares | 5,000,000 | ||||||||||||||||||
Notes Payable Fifteen [Member] | Minimum [Member] | |||||||||||||||||||
Number of warrants | shares | 1,000,000 | ||||||||||||||||||
Notes Payable Sixteen [Member] | |||||||||||||||||||
Percentage of interest rate per annum | 2.00% | ||||||||||||||||||
Debt instrument maturity date description | November 2018 and January 2019 | ||||||||||||||||||
Notes aggregating default amount | 103,000 | $ 193,000 | 103,000 | ||||||||||||||||
Warrant exercise price per share | $ / shares | $ 0.005 | ||||||||||||||||||
Notes Payable Sixteen [Member] | Maximum [Member] | |||||||||||||||||||
Number of warrants | shares | 5,000,000 | ||||||||||||||||||
Notes Payable Sixteen [Member] | Minimum [Member] | |||||||||||||||||||
Number of warrants | shares | 600,000 | ||||||||||||||||||
Notes Payable Seventeen [Member] | |||||||||||||||||||
Debt instrument maturity date description | February 2019 and December 2019 | ||||||||||||||||||
Notes aggregating default amount | $ 479,000 | $ 533,855 | $ 479,000 | ||||||||||||||||
Notes Payable Seventeen [Member] | Maximum [Member] | |||||||||||||||||||
Percentage of interest rate per annum | 3.50% | ||||||||||||||||||
Number of warrants | shares | 39,500,000 | ||||||||||||||||||
Warrant exercise price per share | $ / shares | $ 0.04 | ||||||||||||||||||
Notes Payable Seventeen [Member] | Minimum [Member] | |||||||||||||||||||
Percentage of interest rate per annum | 2.00% | ||||||||||||||||||
Number of warrants | shares | 200,000 | ||||||||||||||||||
Warrant exercise price per share | $ / shares | $ 0.005 | ||||||||||||||||||
Notes Payable Eighteen [Member] | |||||||||||||||||||
Note matures date | Jul. 31, 2019 | ||||||||||||||||||
Percentage of interest rate per annum | 2.00% | ||||||||||||||||||
Notes aggregating default amount | $ 23,000 | ||||||||||||||||||
Number of warrants | shares | 4,600,000 | ||||||||||||||||||
Warrant exercise price per share | $ / shares | $ 0.005 | ||||||||||||||||||
Notes Payable Nineteen [Member] | |||||||||||||||||||
Note matures date | Feb. 29, 2020 | ||||||||||||||||||
Percentage of interest rate per annum | 6.00% | 6.00% | |||||||||||||||||
Notes aggregating default amount | $ 231,478 | $ 231,478 | |||||||||||||||||
Notes Payable Twenty [Member] | |||||||||||||||||||
Percentage of interest rate per annum | 2.00% | 2.00% | |||||||||||||||||
Debt instrument maturity date description | July and September 2019 | ||||||||||||||||||
Notes aggregating default amount | $ 50,000 | $ 50,000 | |||||||||||||||||
Number of warrants | shares | 10,000,000 | 10,000,000 | |||||||||||||||||
Warrant exercise price per share | $ / shares | $ 0.005 | $ 0.005 | |||||||||||||||||
Ira Gaines [Member] | Notes Payable One [Member] | |||||||||||||||||||
Note matures date | Dec. 1, 2017 | ||||||||||||||||||
Percentage of interest rate per annum | 18.00% | ||||||||||||||||||
Lenders [Member] | Notes Payable Three [Member] | |||||||||||||||||||
Debt instrument maturity date description | June 14, 2015 and December 1, 2017 | ||||||||||||||||||
Aggregating loan | 375,994 | 375,994 | $ 375,994 | ||||||||||||||||
Accrued interest | $ 100,000 | $ 100,000 | $ 100,000 | ||||||||||||||||
Lenders [Member] | Notes Payable Three [Member] | Maximum [Member] | |||||||||||||||||||
Percentage of interest rate per annum | 18.00% | 18.00% | 18.00% | ||||||||||||||||
Lenders [Member] | Notes Payable Three [Member] | Minimum [Member] | |||||||||||||||||||
Percentage of interest rate per annum | 2.00% | 2.00% | 2.00% | ||||||||||||||||
Lenders [Member] | Notes Payable Eight [Member] | |||||||||||||||||||
Note matures date | Jul. 5, 2017 | ||||||||||||||||||
Percentage of interest rate per annum | 7.00% |
Derivative Liabilities (Details
Derivative Liabilities (Details Narrative) - USD ($) | Jun. 30, 2019 | Dec. 31, 2018 |
Derivative Instruments and Hedging Activities Disclosure [Abstract] | ||
Derivative liabilities | $ 908,873 | $ 786,706 |
Derivative Liabilities - Schedu
Derivative Liabilities - Schedule of Estimated Fair Value of Derivative Liability Valuation Assumptions (Details) - Black-Scholes Option Pricing Model [Member] | 6 Months Ended |
Jun. 30, 2019 | |
Volatility [Member] | |
Fair value assumptions, measurement input, percentages | 2.0943 |
Risk-Free Interest Rate [Member] | |
Fair value assumptions, measurement input, percentages | 0.0192 |
Expected Dividends [Member] | |
Fair value assumptions, measurement input, percentages | 0 |
Expected Term [Member] | |
Fair value assumptions, measurement input, term | 1 year |
Derivative Liabilities - Sche_2
Derivative Liabilities - Schedule of Valuation of Financial Instruments (Details) - USD ($) | Jun. 30, 2019 | Dec. 31, 2018 |
Total assets | $ 23,672 | $ 91,626 |
Total liabilities | 12,552,994 | $ 11,342,264 |
Level 1 [Member] | ||
Total assets | ||
Conversion option derivative liability | ||
Total liabilities | ||
Level 2 [Member] | ||
Total assets | ||
Conversion option derivative liability | ||
Total liabilities | ||
Level 3 [Member] | ||
Total assets | ||
Conversion option derivative liability | 908,873 | |
Total liabilities | $ 908,873 |
Derivative Liabilities - Sche_3
Derivative Liabilities - Schedule of Reconciliation of Changes in the Fair Value of Derivative Liabilities (Details) | 6 Months Ended |
Jun. 30, 2019USD ($) | |
Derivative liabilities beginning balance | $ 786,706 |
Derivative liabilities ending balance | 908,873 |
Level 3 [Member] | |
Derivative liabilities beginning balance | 786,706 |
Change in fair value | (157,492) |
Partial settlements of liability | (35,325) |
Derivative liabilities ending balance | $ 908,873 |
Capital Structure - Common St_3
Capital Structure - Common Stock and Stock Purchase Warrants (Details Narrative) - $ / shares | Jun. 30, 2019 | Dec. 31, 2018 |
Common stock, shares authorized | 500,000,000 | 500,000,000 |
Common stock, par value | $ 0.0001 | $ 0.0001 |
Common stock, shares outstanding | 445,577,799 | 434,322,574 |
Warrant [Member] | ||
Number of warrants issued during period | 10,000,000 |
Capital Structure - Common St_4
Capital Structure - Common Stock and Stock Purchase Warrants - Schedule of Outstanding Stock Warrants (Details) | 6 Months Ended |
Jun. 30, 2019$ / sharesshares | |
Number of Shares Warrants, Beginning balance | shares | 281,782,856 |
Number of Shares Warrants, Issued | shares | 14,600,000 |
Number of Shares Warrants, Expired and forfeited | shares | (4,159,000) |
Number of Shares Warrants, Exercised | shares | |
Number of Shares Warrants, Ending balance | shares | 292,233,856 |
Exercise Price, Exercised | |
Weighted average price, Beginning balance | 0.09 |
Weighted average price, Issued | .01 |
Weighted average price, Expired and forfeited | 1.25 |
Weighted average price, Exercised | |
Weighted average price, Ending balance | 0.07 |
Minimum [Member] | |
Exercise Price, Beginning balance | 0.001 |
Exercise Price, Issued | .005 |
Exercise Price, Expired and forfeited | 0 |
Exercise Price, Ending balance | .001 |
Maximum [Member] | |
Exercise Price, Beginning balance | 3.74 |
Exercise Price, Issued | .005 |
Exercise Price, Expired and forfeited | 2 |
Exercise Price, Ending balance | $ 3.74 |
Capital Structure - Common St_5
Capital Structure - Common Stock and Stock Purchase Warrants - Summary of Outstanding Warrants (Details) | 6 Months Ended |
Jun. 30, 2019$ / sharesshares | |
Number of Shares | shares | 292,223,856 |
Exercise Price Lower Limit | $ 0.001 |
Exercise Price Upper Limit | $ 3.74 |
Third Quarter 2019 [Member] | |
Number of Shares | shares | 260,000 |
Exercise Price Lower Limit | $ 0.07 |
Exercise Price Upper Limit | $ 0.23 |
Remaining Life (years) | 2 months 30 days |
Fourth Quarter 2019 [Member] | |
Number of Shares | shares | 23,222,726 |
Exercise Price Lower Limit | $ 0.50 |
Exercise Price Upper Limit | $ 1.50 |
Remaining Life (years) | 6 months |
Second Quarter 2020 [Member] | |
Number of Shares | shares | 300,000 |
Exercise Price Upper Limit | $ 0.50 |
Remaining Life (years) | 1 month |
Fourth Quarter 2020 [Member] | |
Number of Shares | shares | 1,000,000 |
Exercise Price Upper Limit | $ 0.20 |
Remaining Life (years) | 1 year 6 months |
First Quarter 2021 [Member] | |
Number of Shares | shares | 12,600,000 |
Exercise Price Upper Limit | $ 0.20 |
Remaining Life (years) | 1 year 9 months |
Second Quarter 2021 [Member] | |
Number of Shares | shares | 5,812,252 |
Exercise Price Lower Limit | $ 0.01408 |
Exercise Price Upper Limit | $ 0.20 |
Remaining Life (years) | 2 years |
Third Quarter 2021 [Member] | |
Number of Shares | shares | 5,166,667 |
Exercise Price Lower Limit | $ 0.03 |
Exercise Price Upper Limit | $ 0.20 |
Remaining Life (years) | 2 years 2 months 30 days |
Fourth Quarter 2021 [Member] | |
Number of Shares | shares | 300,000 |
Exercise Price Upper Limit | $ 0.10 |
Remaining Life (years) | 2 years 6 months |
Second Quarter 2022 [Member] | |
Number of Shares | shares | 1,750,000 |
Exercise Price Upper Limit | $ 0.15 |
Remaining Life (years) | 3 years |
Third Quarter 2022 [Member] | |
Number of Shares | shares | 2,650,000 |
Exercise Price Lower Limit | $ 0.05 |
Exercise Price Upper Limit | $ 0.10 |
Remaining Life (years) | 3 years 2 months 30 days |
Fourth Quarter 2022 [Member] | |
Number of Shares | shares | 9,811,422 |
Exercise Price Lower Limit | $ 0.08 |
Exercise Price Upper Limit | $ 0.29 |
Remaining Life (years) | 3 years 6 months |
First Quarter 2023 [Member] | |
Number of Shares | shares | 8,000,000 |
Exercise Price Lower Limit | $ 0.005 |
Exercise Price Upper Limit | $ 0.04 |
Remaining Life (years) | 3 years 9 months |
Second Quarter 2023 [Member] | |
Number of Shares | shares | 15,000,000 |
Exercise Price Lower Limit | $ 0.005 |
Exercise Price Upper Limit | $ 0.20 |
Remaining Life (years) | 4 years |
Third Quarter 2023 [Member] | |
Number of Shares | shares | 76,700,000 |
Exercise Price Lower Limit | $ 0.005 |
Exercise Price Upper Limit | $ 0.10 |
Remaining Life (years) | 4 years 2 months 30 days |
Fourth Quarter 2023 [Member] | |
Number of Shares | shares | 60,243,000 |
Exercise Price Upper Limit | $ 0.005 |
Remaining Life (years) | 4 years 6 months |
First Quarter 2024 [Member] | |
Number of Shares | shares | 34,600,000 |
Exercise Price Upper Limit | $ 0.005 |
Remaining Life (years) | 4 years 9 months |
Second Quarter 2024 [Member] | |
Number of Shares | shares | 36,363,636 |
Exercise Price Upper Limit | $ 0.005 |
Remaining Life (years) | 5 years |
Third Quarter 2028 [Member] | |
Number of Shares | shares | 3,000,000 |
Exercise Price Upper Limit | $ 0.07 |
Remaining Life (years) | 9 years 2 months 30 days |
Second Quarter 2032 [Member] | |
Number of Shares | shares | 21,807,789 |
Exercise Price Lower Limit | $ 0.01 |
Exercise Price Upper Limit | $ .0679 |
Remaining Life (years) | 13 years |
Stock Compensation (Details Nar
Stock Compensation (Details Narrative) - USD ($) | 3 Months Ended | 6 Months Ended | |||
Jun. 30, 2019 | Jun. 30, 2018 | Mar. 31, 2018 | Jun. 30, 2019 | Jun. 30, 2018 | |
Number of common stock issued for services | |||||
Number of common stock issued for services, value | $ 0 | $ 125,899 | $ 120,000 | $ 426,909 | |
Amortization of prepaid services | $ 0 | $ 101,667 | $ 226,667 | ||
Minimum [Member] | |||||
Consulting fees amortized period | 12 months | ||||
Maximum [Member] | |||||
Consulting fees amortized period | 24 months | ||||
Common Stock [Member] | |||||
Number of common stock issued for services | 0 | 375,000 | 3,000,000 | 3,238,640 | |
Number of common stock issued for services, value | $ 300 | $ 323 | |||
Amortization of prepaid services |
Income Taxes - Results of Ope_2
Income Taxes - Results of Operations (Details Narrative) | 6 Months Ended | 12 Months Ended |
Jun. 30, 2019 | Dec. 31, 2018 | |
Income Tax Disclosure [Abstract] | ||
Income tax examination, description | The impact of U.S. Tax Reform primarily represents the Company's estimates of revaluing the Company's U.S. deferred tax assets and liabilities based on the rates at which they are expected to be recognized in the future. For U.S. federal purposes the corporate statutory income tax rate was reduced from 35% to 21% | |
Percentage of statutory income tax rate | 21.00% | |
Effective tax rate | 0.00% | 0.00% |
Licenses and Supply Agreements
Licenses and Supply Agreements (Details Narrative) - Cytocom Inc., [Member] | May 01, 2018 | Dec. 31, 2014 |
Royalty percentage | 5.00% | |
Maximum [Member] | Restated Agreement [Member] | ||
Royalty percentage | 5.00% | |
Minimum [Member] | Restated Agreement [Member] | ||
Royalty percentage | 1.00% |
Commitments and Contingencies (
Commitments and Contingencies (Details Narrative) - USD ($) | 1 Months Ended | 3 Months Ended | |
Oct. 31, 2013 | Jun. 30, 2019 | Jun. 30, 2018 | |
Rental expense | $ 2,162 | $ 4,451 | |
AHAR Pharma [Member] | |||
Distribution agreement, description | The Company is obligated to provide delivery of an initial supply of between 1 million and 1.5 million doses of Lodonal™ product to cover AHAR Pharma's first-year purchase commitment. |